204 related articles for article (PubMed ID: 20024165)
41. Clinical PDT dose dosimetry for pleural Photofrin-mediated photodynamic therapy.
Sun H; Ong Y; Yang W; Sourvanos D; Dimofte A; Busch TM; Singhal S; Cengel KA; Zhu TC
J Biomed Opt; 2024 Jan; 29(1):018001. PubMed ID: 38223299
[TBL] [Abstract][Full Text] [Related]
42. Molecular determinants of photodynamic therapy for lung cancers.
Usuda J; Ichinose S; Ishizumi T; Ohtani K; Inoue T; Maehara S; Imai K; Shima K; Ohira T; Kato H; Ikeda N
Lasers Surg Med; 2011 Sep; 43(7):591-9. PubMed ID: 22057486
[TBL] [Abstract][Full Text] [Related]
43. Changes in perfusion of mouse tumours after photodynamic therapy.
van Geel IP; Oppelaar H; Oussoren YG; Stewart FA
Int J Cancer; 1994 Jan; 56(2):224-8. PubMed ID: 8314306
[TBL] [Abstract][Full Text] [Related]
44. The characterization of blood flow changes in mouse tumor during Photofrin-based photodynamic therapy by using the color Doppler ultrasonography.
Dubreta K; Ivankovic S; Lovrencic-Huzjan A; Bosnar-Puretic M; Stojkovic R; Jurin M
Oncol Rep; 2009 Nov; 22(5):1253-7. PubMed ID: 19787247
[TBL] [Abstract][Full Text] [Related]
45. In vitro and in vivo photosensitizing applications of Photofrin in malignant melanoma cells.
Chang CJ; Yu JS; Wei FC
Chang Gung Med J; 2008; 31(3):260-7. PubMed ID: 18782948
[TBL] [Abstract][Full Text] [Related]
46. Antitumor effect of photodynamic therapy in mice using direct application of Photofrin dissolved in lidocaine jelly.
Murakami H; Kohno E; Kohmura Y; Ozawa H; Ito H; Sugihara K; Horiuchi K; Hirano T; Kanayama N
Photodermatol Photoimmunol Photomed; 2009 Oct; 25(5):259-63. PubMed ID: 19747245
[TBL] [Abstract][Full Text] [Related]
47. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma.
Ferrario A; von Tiehl KF; Rucker N; Schwarz MA; Gill PS; Gomer CJ
Cancer Res; 2000 Aug; 60(15):4066-9. PubMed ID: 10945611
[TBL] [Abstract][Full Text] [Related]
48. Implications of a pre-existing tumor hypoxic fraction on photodynamic therapy.
Fingar VH; Wieman TJ; Park YJ; Henderson BW
J Surg Res; 1992 Nov; 53(5):524-8. PubMed ID: 1434604
[TBL] [Abstract][Full Text] [Related]
49. Effect of drug-light interval on the mode of action of Photofrin photodynamic therapy in a mouse tumor model.
Li LB; Luo RC
Lasers Med Sci; 2009 Jul; 24(4):597-603. PubMed ID: 18936869
[TBL] [Abstract][Full Text] [Related]
50. Photodynamic activity of lutetium-texaphyrin in a mouse tumor system.
Hammer-Wilson MJ; Ghahramanlou M; Berns MW
Lasers Surg Med; 1999; 24(4):276-84. PubMed ID: 10327046
[TBL] [Abstract][Full Text] [Related]
51. Hypoxia and perfusion labeling during photodynamic therapy.
Busch TM
Methods Mol Biol; 2010; 635():107-20. PubMed ID: 20552343
[TBL] [Abstract][Full Text] [Related]
52. Blood Flow Measurements Enable Optimization of Light Delivery for Personalized Photodynamic Therapy.
Ong YH; Miller J; Yuan M; Chandra M; El Khatib M; Vinogradov SA; Putt ME; Zhu TC; Cengel KA; Yodh AG; Busch TM
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32549354
[TBL] [Abstract][Full Text] [Related]
53. PDT dose dosimetry for Photofrin-mediated pleural photodynamic therapy (pPDT).
Ong YH; Kim MM; Finlay JC; Dimofte A; Singhal S; Glatstein E; Cengel KA; Zhu TC
Phys Med Biol; 2017 Dec; 63(1):015031. PubMed ID: 29106380
[TBL] [Abstract][Full Text] [Related]
54. Photodynamic therapy with verteporfin in the radiation-induced fibrosarcoma-1 tumor causes enhanced radiation sensitivity.
Pogue BW; O'Hara JA; Demidenko E; Wilmot CM; Goodwin IA; Chen B; Swartz HM; Hasan T
Cancer Res; 2003 Mar; 63(5):1025-33. PubMed ID: 12615718
[TBL] [Abstract][Full Text] [Related]
55. Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate.
Henderson BW; Busch TM; Vaughan LA; Frawley NP; Babich D; Sosa TA; Zollo JD; Dee AS; Cooper MT; Bellnier DA; Greco WR; Oseroff AR
Cancer Res; 2000 Feb; 60(3):525-9. PubMed ID: 10676629
[TBL] [Abstract][Full Text] [Related]
56. High-resolution PET imaging for in vivo monitoring of tumor response after photodynamic therapy in mice.
Lapointe D; Brasseur N; Cadorette J; La Madeleine C; Rodrigue S; van Lier JE; Lecomte R
J Nucl Med; 1999 May; 40(5):876-82. PubMed ID: 10319764
[TBL] [Abstract][Full Text] [Related]
57. Induction of systemic neutrophil response in mice by photodynamic therapy of solid tumors.
Cecic I; Parkins CS; Korbelik M
Photochem Photobiol; 2001 Nov; 74(5):712-20. PubMed ID: 11723800
[TBL] [Abstract][Full Text] [Related]
58. Measurement of Cyanine Dye Photobleaching in Photosensitizer Cyanine Dye Conjugates Could Help in Optimizing Light Dosimetry for Improved Photodynamic Therapy of Cancer.
James NS; Cheruku RR; Missert JR; Sunar U; Pandey RK
Molecules; 2018 Jul; 23(8):. PubMed ID: 30042350
[TBL] [Abstract][Full Text] [Related]
59. Reactive Oxygen Species Explicit Dosimetry for Photofrin-mediated Pleural Photodynamic Therapy.
Ong YH; Dimofte A; Kim MM; Finlay JC; Sheng T; Singhal S; Cengel KA; Yodh AG; Busch TM; Zhu TC
Photochem Photobiol; 2020 Mar; 96(2):340-348. PubMed ID: 31729774
[TBL] [Abstract][Full Text] [Related]
60. Hyperthermic potentiation of photodynamic therapy employing Photofrin I and II: comparison of results using three animal tumor models.
Waldow SM; Henderson BW; Dougherty TJ
Lasers Surg Med; 1987; 7(1):12-22. PubMed ID: 2952850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
